Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $7.68 in the prior trading day, Amicus Therapeutics Inc (NASDAQ: FOLD) closed at $6.68, down -13.02%. In other words, the price has decreased by -$13.02 from its previous closing price. On the day, 10.7 million shares were traded. FOLD stock price reached its highest trading level at $7.07 during the session, while it also had its lowest trading level at $6.561.
Ratios:
Our goal is to gain a better understanding of FOLD by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.60 and its Current Ratio is at 3.39. In the meantime, Its Debt-to-Equity ratio is 2.29 whereas as Long-Term Debt/Eq ratio is at 2.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 13, 2024, Downgraded its rating to Equal-Weight and sets its target price to $12 from $17 previously.
On September 06, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $18.
On May 30, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $18.Wells Fargo initiated its Overweight rating on May 30, 2024, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 19 ’25 when Campbell Bradley L sold 400 shares for $10.00 per share. The transaction valued at 4,000 led to the insider holds 1,150,657 shares of the business.
BRADLEY CAMPBELL bought 400 shares of FOLD for $3,940 on Feb 19 ’25. On Dec 02 ’24, another insider, Campbell Bradley L, who serves as the President and CEO of the company, sold 7,500 shares for $10.02 each. As a result, the insider received 75,124 and left with 886,654 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 2056925696 and an Enterprise Value of 2498589440. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.89 while its Price-to-Book (P/B) ratio in mrq is 10.29. Its current Enterprise Value per Revenue stands at 4.73 whereas that against EBITDA is 58.637.
Stock Price History:
The Beta on a monthly basis for FOLD is 0.64, which has changed by -0.3576923 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, FOLD has reached a high of $12.65, while it has fallen to a 52-week low of $6.20. The 50-Day Moving Average of the stock is -17.95%, while the 200-Day Moving Average is calculated to be -32.27%.
Shares Statistics:
The stock has traded on average 3.09M shares per day over the past 3-months and 4707570 shares per day over the last 10 days, according to various share statistics. A total of 299.04M shares are outstanding, with a floating share count of 297.53M. Insiders hold about 3.38% of the company’s shares, while institutions hold 97.34% stake in the company. Shares short for FOLD as of 1744675200 were 17976430 with a Short Ratio of 5.81, compared to 1741910400 on 17454472. Therefore, it implies a Short% of Shares Outstanding of 17976430 and a Short% of Float of 5.88.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of Amicus Therapeutics Inc (FOLD).The consensus estimate for the next quarter is $0.14, with high estimates of $0.22 and low estimates of $0.09.
Analysts are recommending an EPS of between $0.78 and $0.38 for the fiscal current year, implying an average EPS of $0.5. EPS for the following year is $0.81, with 5.0 analysts recommending between $1.2 and $0.64.
Revenue Estimates
10 analysts predict $149.67M in revenue for the current quarter. It ranges from a high estimate of $152.3M to a low estimate of $145.09M. As of the current estimate, Amicus Therapeutics Inc’s year-ago sales were $126.67MFor the next quarter, 10 analysts are estimating revenue of $165.64M. There is a high estimate of $168.13M for the next quarter, whereas the lowest estimate is $163M.
A total of 12 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $647M, while the lowest revenue estimate was $619.5M, resulting in an average revenue estimate of $629.69M. In the same quarter a year ago, actual revenue was $528.29MBased on 12 analysts’ estimates, the company’s revenue will be $771.86M in the next fiscal year. The high estimate is $808.3M and the low estimate is $744.4M.
